NCT00903682 - A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

January 31, 2011

Conditions

HIV InfectionHIVAcquired Immunodeficiency Syndrome

Interventions

DRUG

etravirine (ETR, TMC125)

400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks

DRUG

efavirenz (EFV)

600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks

Trial Locations (33)

Unknown

Salzburg

Vienna

Aarhus

Odense

Bordeaux

Lyon

Nice

Paris

Strasbourg

Berlin

Bonn

Cologne

Essen

Frankfurt

Hamburg

Hanover

Budapest

Haifa

Jerusalem

Ramat Gan

Tel Aviv

Bucharest

Constanța

Moscow

Saint Petersburg

Barcelona

Granada

Madrid

Vigo

Bern

Zurich

Brighton

London